Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | TOP1 | P11387 | 2/20 | 0.46 |
| ▸ | HRAS | P01112 | 9/20 | 0.46 |
| ▸ | ESR1 | P03372 | 9/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25198378 | 0.92 | HDAC1 (0.58) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL30411237 | 0.91 | HDAC1 (0.61) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL25197886 | 0.90 | HDAC1 (0.57) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL30693783 | 0.89 | HDAC1 (0.61) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23744936 | 0.89 | HDAC1 (0.56) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL25695165 | 0.88 | HDAC1 (0.65) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23728551 | 0.88 | HDAC1 (0.56) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23728604 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL25707625 | 0.87 | HDAC1 (0.55) | HDAC1HDAC2HDAC8TOP1HRAS | |
| SCHEMBL23728853 | 0.87 | HDAC1 (0.57) | HDAC1HDAC2HDAC8TOP1HRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124491-A1 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. | 2024-04-18 | — | — | US | disclosed |
| EP-4274583-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150555-A2 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124491-A1 | METHODS AND COMPOUNDS FOR TREATING FRIEDREICH'S ATAXIA | ATXN2, ATXN2L, CDR2 | HDAC1 721/4885HDAC2 1141/4885HDAC8 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.